NASDAQ:OCUL Ocular Therapeutix (OCUL) Stock Price, News & Analysis $8.83 +0.31 (+3.64%) (As of 11/22/2024 ET) Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends About Ocular Therapeutix Stock (NASDAQ:OCUL) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Ocular Therapeutix alerts:Sign Up Key Stats Today's Range$8.41▼$8.8850-Day Range$8.46▼$11.4752-Week Range$2.14▼$11.77Volume819,876 shsAverage Volume947,681 shsMarket Capitalization$1.39 billionP/E RatioN/ADividend YieldN/APrice Target$16.71Consensus RatingModerate Buy Company OverviewOcular Therapeutix, Inc., a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis. It is developing AXPAXLI, an axitinib intravitreal implant that is in phase 3 trials for the treatment of wet age-related macular degeneration and other retinal diseases; PAXTRAVA, a travoprost intracameral implant, which is in phase 2 clinical trials for the treatment of open-angle glaucoma or ocular hypertension; OTX-CSI, a cyclosporine intracanalicular insert that has completed phase 2 clinical trials for the treatment of dry eye disease; and OTX-DED, a dexamethasone intracanalicular insert, which is in phase 2 clinical trials for the short-term treatment of the signs and symptoms of dry eye disease. In addition, the company offers modulator for intermediate and late dry age-related macular degeneration; and gene delivery for inherited retinal degenerations and protein biofactory indications. The company has a strategic collaboration with Regeneron Pharmaceuticals, Inc. (Regeneron) for the development and commercialization of products using the company's sustained-release hydrogel in combination with Regeneron's large molecule VEGF-targeting compounds for the treatment of retinal diseases; and AffaMed Therapeutics Limited for the development and commercialization of DEXTENZA and OTX-TIC. Ocular Therapeutix, Inc. was incorporated in 2006 and is headquartered in Bedford, Massachusetts.Read More… [625,000% Gain] – Are You Ready for the Next Altcoin Boom? (Ad)All of our key indicators are flashing the same signal: an altcoin season is fast approaching. And if you know anything about crypto, you know that altcoin seasons are where some of the biggest gains happen.Register for the FREE Workshop Now & get $10 in Bitcoin Ocular Therapeutix Stock Analysis - MarketRank™See Top Rated MarketRank™ Stocks74th Percentile Overall ScoreOCUL MarketRank™: Ocular Therapeutix scored higher than 74% of companies evaluated by MarketBeat, and ranked 265th out of 953 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.4 / 5Analyst RatingModerate Buy Consensus RatingOcular Therapeutix has received a consensus rating of Moderate Buy. The company's average rating score is 2.86, and is based on 6 buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoverageOcular Therapeutix has only been the subject of 2 research reports in the past 90 days.Read more about Ocular Therapeutix's stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Ocular Therapeutix are expected to decrease in the coming year, from ($0.89) to ($1.00) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Ocular Therapeutix is -6.69, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Ocular Therapeutix is -6.69, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioOcular Therapeutix has a P/B Ratio of 3.94. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted8.06% of the outstanding shares of Ocular Therapeutix have been sold short.Short Interest Ratio / Days to CoverOcular Therapeutix has a short interest ratio ("days to cover") of 11.6, which indicates bearish sentiment.Change versus previous monthShort interest in Ocular Therapeutix has recently decreased by 4.45%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldOcular Therapeutix does not currently pay a dividend.Dividend GrowthOcular Therapeutix does not have a long track record of dividend growth. Sustainability and ESG4.1 / 5Environmental Score-2.01 Percentage of Shares Shorted8.06% of the outstanding shares of Ocular Therapeutix have been sold short.Short Interest Ratio / Days to CoverOcular Therapeutix has a short interest ratio ("days to cover") of 11.6, which indicates bearish sentiment.Change versus previous monthShort interest in Ocular Therapeutix has recently decreased by 4.45%, indicating that investor sentiment is improving. News and Social Media2.5 / 5News Sentiment0.55 News SentimentOcular Therapeutix has a news sentiment score of 0.55. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Ocular Therapeutix this week, compared to 5 articles on an average week.Search Interest13 people have searched for OCUL on MarketBeat in the last 30 days. This is an increase of 44% compared to the previous 30 days.MarketBeat Follows5 people have added Ocular Therapeutix to their MarketBeat watchlist in the last 30 days. This is an increase of 400% compared to the previous 30 days. Company Ownership1.7 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Ocular Therapeutix insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $16,525.00 in company stock.Percentage Held by InsidersOnly 3.50% of the stock of Ocular Therapeutix is held by insiders.Percentage Held by Institutions59.21% of the stock of Ocular Therapeutix is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Ocular Therapeutix's insider trading history. Receive OCUL Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Ocular Therapeutix and its competitors with MarketBeat's FREE daily newsletter. Email Address OCUL Stock News HeadlinesOcular Therapeutix Reports Q3 2024 Financial ResultsNovember 17, 2024 | markets.businessinsider.comOcular Therapeutix (OCUL) Gets a Buy from ScotiabankNovember 16, 2024 | markets.businessinsider.com⭕ [URGENT] Buy Alert just triggeredMy absolute favorite stock just hit a critical "buy now" trigger price.November 23, 2024 | Behind the Markets (Ad)**Ocular Therapeutix, Inc. Announces Third Quarter 2024 Financial Results and Business Highlights** **November 16, 2024 | americanbankingnews.comOcular Therapeutix Inc (OCUL) Q3 2024 Earnings Call Highlights: Strong Financial Position and ...November 16, 2024 | finance.yahoo.comOcular Therapeutix: Strategic Progress and Promising Pipeline Drive Buy RatingNovember 16, 2024 | markets.businessinsider.comOcular Therapeutix price target raised to $15 from $14 at H.C. WainwrightNovember 16, 2024 | markets.businessinsider.comQ3 2024 Ocular Therapeutix Inc Earnings CallNovember 15, 2024 | uk.finance.yahoo.comSee More Headlines OCUL Stock Analysis - Frequently Asked Questions How have OCUL shares performed this year? Ocular Therapeutix's stock was trading at $4.46 at the beginning of 2024. Since then, OCUL shares have increased by 98.0% and is now trading at $8.83. View the best growth stocks for 2024 here. How were Ocular Therapeutix's earnings last quarter? Ocular Therapeutix, Inc. (NASDAQ:OCUL) posted its quarterly earnings data on Wednesday, August, 7th. The biopharmaceutical company reported ($0.26) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.22) by $0.04. The company's revenue was up 7.9% on a year-over-year basis. Who are Ocular Therapeutix's major shareholders? Top institutional investors of Ocular Therapeutix include State Street Corp (2.23%), Geode Capital Management LLC (2.10%), Assenagon Asset Management S.A. (1.81%) and Deltec Asset Management LLC (1.67%). Insiders that own company stock include Summer Road Llc, Antony C Mattessich, Sanjay Nayak, Donald Notman, Philip C Strassburger, Christopher G White and Rabia Gurses Ozden. View institutional ownership trends. How do I buy shares of Ocular Therapeutix? Shares of OCUL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Ocular Therapeutix own? Based on aggregate information from My MarketBeat watchlists, some other companies that Ocular Therapeutix investors own include Humana (HUM), Voyager Therapeutics (VYGR), American Water Works (AWK), Waste Connections (WCN), The RMR Group (RMR), Marinus Pharmaceuticals (MRNS) and DiamondRock Hospitality (DRH). Company Calendar Last Earnings8/07/2024Today11/23/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:OCUL CUSIPN/A CIK1393434 Webwww.ocutx.com Phone(781) 357-4000Fax781-357-4001Employees267Year FoundedN/APrice Target and Rating Average Stock Price Target$16.71 High Stock Price Target$22.00 Low Stock Price Target$11.00 Potential Upside/Downside+89.3%Consensus RatingModerate Buy Rating Score (0-4)2.86 Research Coverage7 Analysts Profitability EPS (Most Recent Fiscal Year)($1.32) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-80,740,000.00 Net Margins-283.74% Pretax Margin-283.74% Return on Equity-45.18% Return on Assets-30.87% Debt Debt-to-Equity Ratio0.19 Current Ratio13.01 Quick Ratio12.94 Sales & Book Value Annual Sales$61.44 million Price / Sales22.59 Cash FlowN/A Price / Cash FlowN/A Book Value$2.24 per share Price / Book3.94Miscellaneous Outstanding Shares157,217,000Free Float151,714,000Market Cap$1.39 billion OptionableOptionable Beta1.26 Social Links 10 Best Stocks to Own in 2025Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2025 and why they should be in your portfolio. Get This Free Report This page (NASDAQ:OCUL) was last updated on 11/23/2024 by MarketBeat.com Staff From Our PartnersMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredBut another coin could soar even higher …Donald Trump wants to be America’s first crypto president. He was the keynote speaker at the recent Bitcoin co...Weiss Ratings | SponsoredElon knows the truth, which is why they want him silencedElon Musk is one of mankind’s greatest innovators. But for all his visionary prowess and contributions to h...Porter & Company | Sponsored24/7 Automated Profits in CryptoThe 4th quarter of 2024 is shaping up to be one of the most explosive periods for crypto in recent memory. But...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Ocular Therapeutix, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Ocular Therapeutix With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.